Motif Biosciences Raises $1M Series C Financing for Diabetes, Asthma Research | GenomeWeb
NEW YORK (GenomeWeb News) — Motif Biosciences has raised $1 million in series C financing to help pay for research into type 2 diabetes and asthma, partner company Amphion Innovations said today.
 
Amphion, which owns 47 percent of Motif, said it was responsible for $400,000 of the financing round.
 
in March, Motif reported receiving $1.8 million in financing, of which $500,000 came from Amphion.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.